Volume 35, Issue 8 (11-2024)
Studies in Medical Sciences 2024, 35(8): 652-661 |
Back to browse issues page
Ethics code: IR.IAU.TMU.REC.1396287
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ehtesham R, Nezhadali M, Hedayati M. ASSOCIATION OF VASPIN RS2236242 GENE POLYMORPHISM WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Studies in Medical Sciences 2024; 35 (8) :652-661
URL: http://umj.umsu.ac.ir/article-1-6338-en.html
URL: http://umj.umsu.ac.ir/article-1-6338-en.html
Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran(Corresponding Author) , ma_nejadali@yahoo.com
Abstract: (598 Views)
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and a major public health problem worldwide. NAFLD has been steadily increasing in prevalence and is associated with serious complications such as cirrhosis and hepatocellular carcinoma, It is also linked to insulin resistance syndrome and cardiovascular diseases. In this study, the association of vaspin rs2236242 gene polymorphism with NAFLD is investigated.
Materials & Methods: The case-control study (random sampling) was conducted on 150 participants, includes 75 participants with non-alcoholic fatty liver diseases as cases and 75 participants as normal group. Participants with a history of alcohol consumption, metabolic disorders or other liver diseases were excluded from the study. The serum vaspin and insulin were measured by ELISA kit and other variables by standard method. Determining the genotypes of rs2236242 was done using the tetra arms polymerase chain reaction. Statistical analysis was performed using SPSS software version 20.
Results: There was no significant difference in vaspin levels in the patients with NAFLD compared with healthy individuals (p ≥0.05). The levels of any of the variables in healthy individuals and patients for GG, AG, and AA genotypes were not significantly different. There was no a significant relationship between rs2236242polymorphism and insulin resistance. No association was found between this polymorphism and NAFLD (p ≥0.05).
Conclusion: The findings showed that there is no relationship between rs2236242 polymorphism with vaspin levels, insulin resistance and non-alcoholic fatty liver disease. However, limitations such as the limited sample size and the use of ultrasound affect the generalizability of the findings.
Materials & Methods: The case-control study (random sampling) was conducted on 150 participants, includes 75 participants with non-alcoholic fatty liver diseases as cases and 75 participants as normal group. Participants with a history of alcohol consumption, metabolic disorders or other liver diseases were excluded from the study. The serum vaspin and insulin were measured by ELISA kit and other variables by standard method. Determining the genotypes of rs2236242 was done using the tetra arms polymerase chain reaction. Statistical analysis was performed using SPSS software version 20.
Results: There was no significant difference in vaspin levels in the patients with NAFLD compared with healthy individuals (p ≥0.05). The levels of any of the variables in healthy individuals and patients for GG, AG, and AA genotypes were not significantly different. There was no a significant relationship between rs2236242polymorphism and insulin resistance. No association was found between this polymorphism and NAFLD (p ≥0.05).
Conclusion: The findings showed that there is no relationship between rs2236242 polymorphism with vaspin levels, insulin resistance and non-alcoholic fatty liver disease. However, limitations such as the limited sample size and the use of ultrasound affect the generalizability of the findings.
References
1. Kounatidis D, Vallianou NG, Geladari E, Panoilia MP, Daskou A, Stratigou T, et al. NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics. Biomedicines 2024; 12(4):826 [DOI:10.3390/biomedicines12040826] [PMID] []
2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77(4):1335-47 [DOI:10.1097/HEP.0000000000000004] [PMID] []
3. Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN. Metabolic-associated fatty liver disease: A selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Front Med 2024; 11:1291501 [DOI:10.3389/fmed.2024.1291501] [PMID] []
4. Genua I, Cusi K. Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies. Diabetes Spectr 2024; 37(1):48-58 [DOI:10.2337/dsi23-0012] [PMID] []
5. Matsubayashi Y, Fujihara K, Yamada-Harada M, Mitsuma Y, Sato T, Yaguchi Y, et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol 2022; 21(1):90 [DOI:10.1186/s12933-022-01518-4] [PMID] []
6. Zhu Y, Ke Y, Hu Y, Wu K, Liu S, Hu J. Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis 2022; 21(1):57 [DOI:10.1186/s12944-022-01658-2] [PMID] []
7. Esteghamati A, Noshad S, Mousavizadeh M, Zandieh A, Nakhjavani M. Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance. Diabetes Metab J 2014; 38:143-9 [DOI:10.4093/dmj.2014.38.2.143] [PMID] []
8. Jakubek-Kipa K, Galiniak S, Mazur A. Progranulin and Vaspin as Potential Novel Markers in the Etiology of Type 1 Diabetes in Children. Medicina 2024; 60(7):1165 [DOI:10.3390/medicina60071165] [PMID] []
9. Rui H, Yu H, Zou D, Chi K, Xu P, Song X, et al. Vaspin alleviates pathological cardiac hypertrophy by regulating autophagy-dependent myocardial senescence. Emerg Crit Care Med 2024; 4(1):4-15 [DOI:10.1097/EC9.0000000000000097]
10. Shilpa A, Prasanna JS. A comparative evaluation of adipokine VASPIN in female obese and non-obese subjects with periodontitis and health. J Oral Res Rev 2024; 16(1):21-7 [DOI:10.4103/jorr.jorr_34_23]
11. Pilarski Ł, Pelczyńska M, Koperska A, Seraszek-Jaros A, Szulińska M, Bogdański P. Association of serum vaspin concentration with metabolic disorders in obese individuals. Biomolecules 2023; 13(3):508 [DOI:10.3390/biom13030508] [PMID] []
12. Zain SM, Pung YF, Mohamed R. Association of vaspin rs2236242 with type 2 diabetes mellitus and obesity: a meta-analysis of case-control studies. J Diabetes Metab Disord 2023; 22(1):237-43 [DOI:10.1007/s40200-022-01119-8] [PMID] []
13. Torki S, Nezhadali M, Hedayati M, Karimi H, Razavi SA, Najd Hassan Bonab L. The role of rs2236242 at SERPINA12 gene and vaspin level on papillary thyroid carcinoma. Nucleosides Nucleotides Nucleic Acids 2024:1-12 [DOI:10.1080/15257770.2024.2354427] [PMID]
14. Hashemi M, Rezaei H, Eskandari-Nasab E, Zakeri Z, Taheri M. Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report. Gene 2012; 510(2):113-7 [DOI:10.1016/j.gene.2012.08.048] [PMID]
15. Asal DM, Mesbah NM, Abo-Elmatty DM, Fathy H, Abdel-Hamed AR. Association of vaspin rs2236242 and Val109Asp omentin genes polymorphism and their serum levels with increased risk of breast cancer. Meta Gene 2022; 31:101016 [DOI:10.1016/j.mgene.2022.101016]
16. Hosseini M, Nezhadali M, Hedayati M. Association of vaspin rs2236242 gene polymorphism with serum vaspin level, insulin resistance and diabetes in an Iranian diabetic/pre-diabetic population. J Med Biochem 2021; 40(1):33 [DOI:10.5937/jomb0-24671] [PMID] []
17. Ehtesham R, Hedayati M. Correlation of vaspin levels with anthropometric and biochemical parameters in patients with Non-alcoholic fatty liver disease in an Iranian population. Yafteh 2021; 23(3) [google scholar]
18. Bahar A, Azizi F. Insulin Resistance and Cell Function in Patients E with Chronic Hepatitis and Impaired Glucose Tolerance. Int J Endocrinol Metab 2007; 4: 125-33 [google scholar]
19. Zarei A, Kohan L, Fallahi S. Association of vaspin rs2236242 gene polymorphism with overweight and obesity in Iranian women. Iran J Endocrinol Metab 2014; 16(1):20-5 [google scholar]
20. Montazerifar F, Bakhshipour ARR, Karajibani M, Torki Z, Dashipour AR. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci 2017; 22: 70 [DOI:10.4103/jrms.JRMS_788_16] [PMID] []
21. Byoumy EM, Sayed MM, El-Rahman SA, Al-Nakib SA, Salama MM, Mohamed MG. Relationship of serum vaspin, nafld fibrosis score to ultrasonographic detection and quantification of steatosis in nonalcoholic fatty liver disease patients. QJM 2021; 114(Supplement_1):hcab100-22 [DOI:10.1093/qjmed/hcab100.122]
22. Yilmaz Y, Kurt R, Gurdal A, Alahdab YO, Yonal O, Senates E, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 2011; 217(1):125-9 [DOI:10.1016/j.atherosclerosis.2011.03.026] [PMID]
23. Feng R, Li Y, Wang C, Luo C, Liu L, Chuo F, et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract 2014; 106:88-94 [DOI:10.1016/j.diabres.2014.07.026] [PMID]
24. Mehrabani S, Arab A, Karimi E, Nouri M, Mansourian M. Blood circulating levels of Adipokines in polycystic ovary syndrome patients: a systematic review and Meta-analysis. Reprod Sci 2021; 28:3032-50 [DOI:10.1007/s43032-021-00709-w] [PMID]
25. Lin K, Sun X, Wang X, Wang H, Chen X. Circulating Adipokine levels in nonobese women with polycystic ovary syndrome and in nonobese control women: a systematic review and Meta-analysis. Front Endocrinol 2020; 11:537809 [DOI:10.3389/fendo.2020.537809] [PMID] []
26. Fenga RN, Wang C, Sun CH, Guo FC, Zhao C, Li Y. Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study. Asian Biomed 2011; 5 (4): 525-9 [DOI:10.5372/1905-7415.0504.069]
27. Alnory A, Gad H, Hegazy G, Shaker O. The association of vaspin rs2236242 and leptin rs7799039 polymorphism with metabolic syndrome in Egyptian women. Turk J Med Sci 2016; 46(5): 1335-40 [DOI:10.3906/sag-1502-138] [PMID]
28. Abdelhamid AM, Zaafan MA. Association of chemerin rs17173608 and vaspin rs2236242 polymorphisms with type two diabetes mellitus and its impact on their corresponding serum levels in Egyptian population. Ideas 2019; 15(3): 1-6 [DOI:10.26717/BJSTR.2019.15.002694]
29. Kempf K, Rose B, Illig T, Rathmann W, Strassburger K, Thorand B, et al. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp Clin Endocrinol Diabetes 2010; 118(03): 184-9 [DOI:10.1055/s-2008-1081499] [PMID]
30. Abdel Ghany SM, Sayed AA, El-deek SEM, Elbadre HM, Dahpy MA, Saleh MA, et al. Obesity risk prediction among women of Upper Egypt: the impact of serum vaspin and vaspin rs2236242 gene polymorphism. Gene 2017; 626: 140-8 [DOI:10.1016/j.gene.2017.05.007] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
